Alcatel-Lucent acquires OpenPlug, a cross-platform mobile software development tool provider
Paris, September 1, 2010 Acquisition expands company’s developer tools to make applications available on diverse operating systems and in more service provider stores
Alcatel-Lucent (Euronext Paris and NYSE: ALU) today announced that it has acquired OpenPlug, a mobile software and applications development tools vendor. Through this acquisition, Alcatel-Lucent deepens its role in the applications space by delivering, as part of its integrated suite of developer tools, a platform where application developers can write an application once, which will then be translated to run on any of the five major mobile operating systems. Terms of the
The article [click here]
IntegraGen lists on NYSE Alternext
Paris, 18 June 2010
NYSE Euronext today announced the admission of IntegraGen, a pioneer in the development of molecular diagnostic tools, to NYSE Alternext.
IntegraGen is a major contender in clinical genomics, where it is developing a line of productsand services for genetic diagnostic, the most dynamic segment of the in-vitro diagnostics market.
The company offers clinical practitioners new diagnostic tools that favour the deployment of personalized treatment for complex illnesses in autism and oncology.
IntegraGen (ticker symbol: ALINT) was admitted to NYSE Alternext by direct listing of the 3,771,471 existing shares making
The article [click here]
Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
Freising, Germany, June 15, 2010
--Anti-VEGF PRS-050 is first Anticalin tested in humans--
Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin. The trial is an open-label, dose-escalating evaluation of the compound’s safety and tolerability in patients with solid tumors. Conducted at three sites in Germany, the trial is underway and patients from the first cohort have been dosed.
“Meeting our goal of initiating this trial in the first half of 2010 demonstrates Pieris’ commitment to establishing the safety and the therapeutic relevance of the
The article [click here]
Pieris AG Appoints Chief Scientific Officer
Freising, Germany, June 07, 2010
Pieris AG announced today that Laurent Audoly, Ph.D., has joined the company as Chief Scientific Officer,effective immediately. Dr. Audoly, most recently Biologics Research Site Lead at Merck & Co. Inc., brings both pharma and biotech experience, with extensive expertise in therapeutic protein drug development.
“Laurent has an impressive track record of leading teams and moving discovery programs successfully from target identification into and through the clinic. In particular, his pharmacology expertise and drug development skills are the precise ingredients we need to maximize the value of our
The article [click here]
Ubidyne Named GSMA 2010 Mobile Innovation Grand Prix Global Champion
MOBILE WORLD CONGRESS 2010 — BARCELONA, SPAIN
FEBRUARY 17, 2010
Ubidyne, the leader in radio technology for the wireless industry, announced today that the company was named the Mobile Innovation Grand Prix Champion at this year’s Mobile World Congress for its breakthrough Antenna Embedded Radio™ technology.
Ubidyne’s winning innovation, the Antenna Embedded Radio, provides a better, more cost effective way for mobile network operators to transmit broadband signals to subscribers using next generation networks. The Antenna Embedded Radio shrinks inefficient analog circuitry down to inexpensive modular digital circuits that attach
The article [click here]
Pieris Appoints a New CEO
Freising, January 4th, 2010
Appointment will bring substantial deal-making expertise to the company
Pieris AG today announced the appointment of Stephen S. Yoder as CEO with immediate effect. Mr. Yoder takes over the position from interim CEO and co-founder Claus Schalper, who will remain CFO. Mr. Yoder joins Pieris from MorphoSys AG, where he was General Counsel and Head of Licensing & IP, responsible for company-wide legal & IP, as well as several areas in business development.
“We are delighted to have Steve on board to help drive the value of Pieris’ proprietary Anticalin technology”, commented Dr. Hans A. Kuepper, chairman of
The article [click here]
